These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22369322)

  • 1. Decitabine for acute myeloid leukemia.
    Marks PW
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):299-305. PubMed ID: 22369322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
    Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
    J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
    Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
    Schwartsmann G; Fernandes MS; Schaan MD; Moschen M; Gerhardt LM; Di Leone L; Loitzembauer B; Kalakun L
    Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine dosage in myelodysplastic syndromes.
    Giagounidis AA
    Blood; 2007 Aug; 110(3):1082-3; author reply 1083. PubMed ID: 17644750
    [No Abstract]   [Full Text] [Related]  

  • 9. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
    Cashen AF; Devine H; DiPersio J
    Am J Hematol; 2006 Jul; 81(7):543-5. PubMed ID: 16755561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
    Issa JP
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
    Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
    Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
    Kipp D; H Wei A
    Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
    Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
    Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.